Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, Spratt SK, Surosky RT, Giedlin MA, Nichol G, Holmes MC, Gregory PD, Ando DG, Kalos M, Collman RG, Binder-Scholl G, Plesa G, Hwang WT, Levine BL, June CH.

N Engl J Med. 2014 Mar 6;370(10):901-10. doi: 10.1056/NEJMoa1300662.

2.

CD4+ count-guided interruption of antiretroviral treatment.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C.

N Engl J Med. 2006 Nov 30;355(22):2283-96.

3.

A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy.

Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, Macken C, Richman DD, Christopherson C, June CH, Lazar R, Broad DF, Jalali S, Hege KM.

Mol Ther. 2002 Jun;5(6):788-97.

4.

Positive results with autologous transplant of ZFN-modified CD4 T-cells: a step toward a practical, functional cure for HIV.

[No authors listed]

AIDS Patient Care STDS. 2011 Nov;25(11):693. doi: 10.1089/apc.2011.9865. No abstract available.

PMID:
22023317
5.

Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy.

Le T, Wright EJ, Smith DM, He W, Catano G, Okulicz JF, Young JA, Clark RA, Richman DD, Little SJ, Ahuja SK.

N Engl J Med. 2013 Jan 17;368(3):218-30. doi: 10.1056/NEJMoa1110187.

6.

Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.

Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT Jr, Walker RE, Polis MA, Spooner K, Metcalf JA, Baseler M, Fyfe G, Lane HC.

N Engl J Med. 1996 Oct 31;335(18):1350-6.

7.

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, Merigan TC.

Ann Intern Med. 1996 Jun 15;124(12):1039-50.

PMID:
8633817
8.

Effect of influenza virus vaccine on the expression of human immunodeficiency virus co-receptor CCR5.

Rucker RP, Day NK, Good RA, Kamchaisatian W, Emmanuel P, Sleasman JW, Mayeski C, Dinglasan E, Haraguchi S, Tangsinmankong N.

Ann Allergy Asthma Immunol. 2004 Sep;93(3):272-6.

PMID:
15478388
9.

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.

Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.

AIDS. 2008 Aug 20;22(13):1583-8. doi: 10.1097/QAD.0b013e328305bd77.

PMID:
18670217
10.

A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.

Lopez Bernaldo de Quiros JC, Miro JM, Peña JM, Podzamczer D, Alberdi JC, Martínez E, Cosin J, Claramonte X, Gonzalez J, Domingo P, Casado JL, Ribera E; Grupo de Estudio del SIDA 04/98.

N Engl J Med. 2001 Jan 18;344(3):159-67.

11.

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD.

N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20.

12.

Impact of highly active antiretroviral treatment on expression of HIV-1 coreceptors and ligand levels in peripheral blood from HIV-1 infected patients in China.

Fang J, Bai S, Wu L, Zhu X, Yao X, Jin C, Wang C.

J Int Med Res. 2013 Oct;41(5):1560-9. doi: 10.1177/0300060513495628. Epub 2013 Sep 16.

PMID:
24043708
13.

Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.

Price DA, Scullard G, Oxenius A, Braganza R, Beddows SA, Kazmi S, Clarke JR, Johnson GE, Weber JN, Phillips RE.

J Virol. 2003 May;77(10):6041-9.

14.

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.

Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, Schneider T, Hofmann J, Kücherer C, Blau O, Blau IW, Hofmann WK, Thiel E.

N Engl J Med. 2009 Feb 12;360(7):692-8. doi: 10.1056/NEJMoa0802905.

15.

Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.

Plana M, García F, Gallart T, Tortajada C, Soriano A, Palou E, Maleno MJ, Barceló JJ, Vidal C, Cruceta A, Miró JM, Gatell JM.

AIDS. 2000 Sep 8;14(13):1921-33.

PMID:
10997396
16.

Interleukin-2 therapy in patients with HIV infection.

INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D.

N Engl J Med. 2009 Oct 15;361(16):1548-59. doi: 10.1056/NEJMoa0903175.

17.

Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection.

Ananworanich J, Schuetz A, Vandergeeten C, Sereti I, de Souza M, Rerknimitr R, Dewar R, Marovich M, van Griensven F, Sekaly R, Pinyakorn S, Phanuphak N, Trichavaroj R, Rutvisuttinunt W, Chomchey N, Paris R, Peel S, Valcour V, Maldarelli F, Chomont N, Michael N, Phanuphak P, Kim JH; RV254/SEARCH 010 Study Group.

PLoS One. 2012;7(3):e33948. doi: 10.1371/journal.pone.0033948. Epub 2012 Mar 30.

18.

Autologous CCR5-modified CD4 T-cells effective in HAART nonresponders.

[No authors listed]

AIDS Patient Care STDS. 2011 Nov;25(11):693. No abstract available.

PMID:
22132424
19.

Breast milk CD4+ T cells express high levels of C chemokine receptor 5 and CXC chemokine receptor 4 and are preserved in HIV-infected mothers receiving highly active antiretroviral therapy.

Kourtis AP, Ibegbu CC, Theiler R, Xu YX, Bansil P, Jamieson DJ, Lindsay M, Butera S, Duerr A.

J Infect Dis. 2007 Apr 1;195(7):965-72. Epub 2007 Feb 20.

20.

Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV.

Tebas P, Stein D, Binder-Scholl G, Mukherjee R, Brady T, Rebello T, Humeau L, Kalos M, Papasavvas E, Montaner LJ, Schullery D, Shaheen F, Brennan AL, Zheng Z, Cotte J, Slepushkin V, Veloso E, Mackley A, Hwang WT, Aberra F, Zhan J, Boyer J, Collman RG, Bushman FD, Levine BL, June CH.

Blood. 2013 Feb 28;121(9):1524-33. doi: 10.1182/blood-2012-07-447250. Epub 2012 Dec 20. Erratum in: Blood. 2014 Jul 24;124(4):663.

Items per page

Supplemental Content

Write to the Help Desk